Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes

Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-fusion Protein

(2022) Julie S Moyers et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The future of insulin therapy

(2021) Tim Heise   DIABETES RESEARCH AND CLINICAL PRACTICE

237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes

(2020) ULRIKE HÖVELMANN et al.   DIABETES

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

(2020) Julio Rosenstock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes

(2019) Vivian T Thieu et al.   Patient Preference and Adherence

Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set

(2018) Kevin M. Pantalone et al.   DIABETES CARE

Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment

(2018) Simon Fifer et al.   BMC HEALTH SERVICES RESEARCH

Design and Conduct Considerations for First-in-Human Trials

(2018) Jie Shen et al.   CTS-Clinical and Translational Science

Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes

(2016) C. Victor Spain et al.   CLINICAL THERAPEUTICS

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

(2016) Z. Milicevic et al.   DIABETES OBESITY & METABOLISM

Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database

(2016) Maureen Lage et al.   Patient Preference and Adherence

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

(2016) Karel Kostev et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

(2015) R. H. A. Becker et al.   DIABETES OBESITY & METABOLISM

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

(2015) Tim Heise et al.   Expert Opinion on Drug Metabolism & Toxicology

Defining the Role of Medication Adherence in Poor Glycemic Control among a General Adult Population with Diabetes

(2014) Becca S. Feldman et al.   PLoS One

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review

(2013) M. J. Davies et al.   DIABETIC MEDICINE

Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences

(2013) Tim Heise et al.   Endocrine Practice

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

The Future of Basal Insulin Supplementation

(2011) Airin C.R. Simon et al.   Diabetes Technology & Therapeutics

Barriers to Insulin Injection Therapy

(2009) Richard R. Rubin et al.   DIABETES EDUCATOR

Restaging insulin therapy for patients with type 2 diabetes

(2009) A. J. Garber   DIABETES OBESITY & METABOLISM